{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:47:53Z","timestamp":1771660073460,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme Corp.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.vaccine.2011.11.096","type":"journal-article","created":{"date-parts":[[2011,12,10]],"date-time":"2011-12-10T19:30:41Z","timestamp":1323545441000},"page":"904-910","source":"Crossref","is-referenced-by-count":56,"title":["Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults \u226560 years of age"],"prefix":"10.1016","volume":"30","author":[{"given":"Joost N.","family":"Vermeulen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep M.A.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick H.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Poland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron J.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Chalikonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Caulfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon E.","family":"Stek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan S.F.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert","family":"Vessey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian P.","family":"Sch\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula W.","family":"Annunziato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Schlienger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Silber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.11.096_bib0005","series-title":"Mucocutaneous manifestations of viral diseases","first-page":"98","article-title":"Varicella zoster virus","author":"Creed","year":"2010"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0015","unstructured":"FDA licenses new vaccine to reduce older Americans\u2019 risk of shingles [press release]. U.S. Food and Drug Administration. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2006\/ucm108659.htm [accessed August 20, 2011]; May 26, 2006."},{"key":"10.1016\/j.vaccine.2011.11.096_bib0020","unstructured":"EMEA Committee for Medical Products for Human Use: March 2006 monthly report. Available at: http:\/\/www.emea.europa.eu\/pdfs\/human\/press\/pr\/10293706en.pdf [accessed December 12, 2006]."},{"key":"10.1016\/j.vaccine.2011.11.096_bib0025","unstructured":"Recommendations of the Advisory Committee on Immunization Practices, Centers for Disease Control. Prevention of herpes zoster. Available at: http:\/\/www.cdc.gov\/mmwr\/pdf\/rr\/rr5705.pdf [accessed August 20, 2008]."},{"key":"10.1016\/j.vaccine.2011.11.096_bib0030","unstructured":"Centers for Disease Control. National immunization program. Adult immunization schedule. Available at: http:\/\/www.cdc.gov\/nip\/recs\/adult-schedule.htm [accessed November 27, 2006]."},{"key":"10.1016\/j.vaccine.2011.11.096_bib0035","unstructured":"FDA approves Zostavax vaccine to prevent shingles in individuals 50 to 59 years of age [press release]. U.S. Food and Drug Administration. Available at: http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm248390.htm [accessed March 30, 2011]; March 24, 2011."},{"key":"10.1016\/j.vaccine.2011.11.096_bib0040","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1128\/IAI.32.1.24-27.1981","article-title":"Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged","volume":"32","author":"Berger","year":"1981","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0045","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1212\/WNL.30.6.582","article-title":"Selective decline in cellular immune responses to varicella-zoster in the elderly","volume":"30","author":"Miller","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00916011","article-title":"Lymphocyte responses to varicella zoster virus in the elderly","volume":"7","author":"Hayward","year":"1987","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/infdis\/166.2.253","article-title":"Immune response of elderly individuals to a live attenuated varicella vaccine","volume":"166","author":"Levin","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0065","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1086\/605611","article-title":"Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine","volume":"200","author":"Weinberg","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0070","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/379048","article-title":"Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine","volume":"188","author":"Levin","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0075","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1016\/S0264-410X(03)00303-7","article-title":"Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay","volume":"21","author":"Takahashi","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0080","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2011.11.096_bib0085","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/jmv.20754","article-title":"The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection","volume":"78","author":"Hammond","year":"2006","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0090","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/CDLI.8.5.871-879.2001","article-title":"Development and validation of a gamma interferon ELISPOT assay for quantification of cellular immune responses to varicella-zoster virus","volume":"8","author":"Smith","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jmv.10318","article-title":"Measurement of cell-mediated immunity with a varicella-zoster virus-specific interferon-\u03b3 ELISPOT assay: responses in an elderly population receiving a booster immunization","volume":"70","author":"Smith","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0100","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post design","volume":"62","author":"Liang","year":"2000","journal-title":"Sankhy\u0101: Indian J Stat"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0105","doi-asserted-by":"crossref","first-page":"7087","DOI":"10.1016\/j.vaccine.2007.07.051","article-title":"Phenotypic and functional characterization of ex-vivo T cell responses to the live attenuated herpes zoster vaccine","volume":"25","author":"Patterson-Bartlett","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0110","unstructured":"FDA\/CBER resource page. Slides for ZOSTAVAX\u2122 (zoster vaccine live) Vaccines and Related Biological Products Advisory Committee Meeting, 15-Dec-2005. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/05\/slides\/5-4198S2_2.pdf [accessed January 27, 2011]."},{"key":"10.1016\/j.vaccine.2011.11.096_bib0115","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.vaccine.2006.11.011","article-title":"Safety and immunogenicity of a high-potency zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults","volume":"25","author":"Macaladad","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0120","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1532-5415.2007.01397.x","article-title":"Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older","volume":"55","author":"Kerzner","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0125","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.vaccine.2006.10.027","article-title":"Safety and tolerability of a high-potency zoster vaccine in adults >=50 years of age","volume":"25","author":"Tyring","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0130","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/CVI.00310-07","article-title":"A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of ZOSTAVAX\u00ae","volume":"15","author":"Gilderman","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4161\/hv.6.11.12852","article-title":"Concomitant administration of zoster and pneumococcal vaccines in adults \u226560 years old","volume":"6","author":"MacIntyre","year":"2010","journal-title":"Hum Vaccines"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0140","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1016\/j.vaccine.2010.04.003","article-title":"Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster","volume":"28","author":"Mills","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.11.096_bib0145","doi-asserted-by":"crossref","unstructured":"Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman K, Williams H, et al. for the Shingles Prevention Study Group. Safety profile of a herpes zoster vaccine. A detailed review of data from CSP #403: the Shingles Prevention Study. Ann Intern Med 2010;152:545\u201354.","DOI":"10.7326\/0003-4819-152-9-201005040-00004"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11018925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11018925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T16:03:18Z","timestamp":1593360198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11018925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0264410X11018925"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.11.096","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}